



March 2, 2020

Acenxion Biosystems announces founding CEO and Board of Directors

[Kansas City, KS] Acenxion Biosystems today announced that Dr. Roy Swiger will formally be joining the company as CEO and Director effective today.

From his time at Lawrence Livermore National Laboratory, to his work as a Director at MRI Global, and his most recent efforts as CEO of ImpeDx Diagnostics, Dr. Swiger's leadership and laboratory skills have generated significant value and resulted in several successful product releases.

"I, as others, have a deep, personal connection to the work this company is doing. This is possibly the strongest team I've been a part of, and I am extremely confident in the abilities and dedication they all bring to the company's efforts." Swiger said. Howard Goldstein added, since my time working with Roy at IntegenX, I've always been impressed with his technical precision and integration of a strong business case with the related laboratory and product development work."

Joining Dr. Swiger on the Board of Directors will be:

- Howard Goldstein, Chair – Independent consultant and advisor in the biotech industry
- Dr. Wayne Carter, Vice Chair and Independent Director – CEO, TVAX Biomedical
- Brian Struchtemeyer, Treasurer and Secretary – Managing Director, Grey Iris Holdings

Acenxion Biosystems (ACXBIO) is a privately funded company developing automated systems for bacteria detection in blood cultures and phenotypic antimicrobial susceptibility testing (AST). Seamlessly fitting into current clinical workflows, Acenxion's scalable AST system reduces the time required for phenotypic testing to just 4-6 hours allowing clinicians rapid use of a precise, targeted treatment. Acenxion's technology improves patient outcomes, reduces healthcare costs, and reduces the spread of antibiotic resistance extending the service life of antibiotics.